Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis
PLOS One · 2025
DOI: 10.1371/journal.pone.0328015 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Nicha Wongjarupong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota, United States of America. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Intestinal Obstruction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, National Institutes of Health's National Center for Advancing Translational Sciences, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Background
Gastrointestinal (GI) complications are the second most common disorders in persons with cystic fibrosis (PwCF). There is limited data on how having a dedicated CF-GI clinic and cystic fibrosis transmembrane conductance regulator (CFTR) modulators may affect rates of GI complications. Our aim was to assess the effect of the CF-GI clinic and CFTR modulators on GI complications with incidence of distal intestinal obstructive syndrome (DIOS).
Methods
This was a retrospective study of adult PwCF who were seen in a CF-GI clinic from 2000–2023. Comparisons were made between the numbers of admissions and emergency department (ED) visits for DIOS at three years before and after CFTR modulator use and the first CF-GI clinic visit.
Results
Of the 1,076 PwCF identified, 242 were seen in CF-GI clinic. Of this, 126 (52.1%) were female, with a median age of 40 (IQR: 30–47) years. There were 146 (60.3%) with regular use of laxatives. Of the 59 PwCF with CF-GI clinic visits for constipation, hospital admissions decreased in 16, were unchanged in 32, and increased in 11 ( p = 0.402) while ED visits decreased in 9, remained the same in 40, and increased in 10 ( p = 0.862). Of the 125 PwCF with CFTR modulator use, DIOS-related hospital admissions decreased in 15 patients, remained unchanged in 89, and increased in 21 ( p = 0.021) while ED visits were fewer in 8, unchanged in 97, and increased in 20 ( p = 0.587).
Conclusion
PwCF had high burden of constipation with a majority of patients regularly using laxatives, and almost half had a history of DIOS. CFTR modulator use and CF-GI clinic were not associated with a decrease of DIOS incidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota, United States of America.
- Department of Medicine, Division of Gastroenterology and Hepatology, Bangkok Hospital Pattaya, Chonburi, Thailand.
- University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America.
- Gastroenterology Section, Minneapolis VA Health Care System, Minneapolis, Minnesota, United States of America.
- Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, United States of America.
ORCID-Profile: Nicha Wongjarupong, Ashley Benner
Förderung
- NCATS NIH HHS
- National Institutes of Health's National Center for Advancing Translational Sciences
- Cystic Fibrosis Foundation
Zitieren
APA
Wongjarupong, N., Delbrune, M. F., Alp, J., Moutsoglou, D. M., Wiggen, T., Benner, A., Billings, J. L., Dunitz, J. M., Schwarzenberg, S. J., Moshiree, B., & Sultan, S. (2025). Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis. PLOS One. https://doi.org/10.1371/journal.pone.0328015
Vancouver
Wongjarupong N, Delbrune MF, Alp J, Moutsoglou DM, Wiggen T, Benner A, et al. Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis. PLOS One. 2025. doi:10.1371/journal.pone.0328015
BibTeX
@article{Wongjarupong2025,
author = {Wongjarupong, Nicha and Delbrune, Malique F and Alp, Jameel and Moutsoglou, Daphne M and Wiggen, Talia and Benner, Ashley and Billings, Joanne L and Dunitz, Jordan M and Schwarzenberg, Sarah J and Moshiree, Baharak and Sultan, Shahnaz},
title = {Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0328015}
}
EUVIMED